135 related articles for article (PubMed ID: 38115208)
1. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2023 Dec; 3(12):2572-2584. PubMed ID: 38115208
[TBL] [Abstract][Full Text] [Related]
2. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus
Beatty GL; Shahda S; Beck T; Uppal N; Cohen SJ; Donehower R; Gabayan AE; Assad A; Switzky J; Zhen H; Von Hoff DD
Oncologist; 2019 Jan; 24(1):14-e10. PubMed ID: 30115734
[TBL] [Abstract][Full Text] [Related]
4. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
5. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
8. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Mitchell TC; Hamid O; Smith DC; Bauer TM; Wasser JS; Olszanski AJ; Luke JJ; Balmanoukian AS; Schmidt EV; Zhao Y; Gong X; Maleski J; Leopold L; Gajewski TF
J Clin Oncol; 2018 Nov; 36(32):3223-3230. PubMed ID: 30265610
[TBL] [Abstract][Full Text] [Related]
9. ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Johnson M; Dudek AZ; Sukari A; Call J; Kunk PR; Lewis K; Gainor JF; Sarantopoulos J; Lee P; Golden A; Harney A; Rothenberg SM; Zhang Y; Goldman JW
Clin Cancer Res; 2022 Jun; 28(12):2517-2526. PubMed ID: 35302585
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E; Sukari A; Lakhani NJ; Patnaik A; Lou Y; Im SA; Golan T; Geva R; Wermke M; de Miguel M; Palcza J; Jha S; Chaney M; Abraham AK; Healy J; Falchook GS
ESMO Open; 2022 Dec; 7(6):100639. PubMed ID: 36493599
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Phillips TJ; Forero-Torres A; Sher T; Diefenbach CS; Johnston P; Talpaz M; Pulini J; Zhou L; Scherle P; Chen X; Barr PM
Blood; 2018 Jul; 132(3):293-306. PubMed ID: 29695516
[TBL] [Abstract][Full Text] [Related]
12. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Schroeder MA; Khoury HJ; Jagasia M; Ali H; Schiller GJ; Staser K; Choi J; Gehrs L; Arbushites MC; Yan Y; Langmuir P; Srinivas N; Pratta M; Perales MA; Chen YB; Meyers G; DiPersio JF
Blood Adv; 2020 Apr; 4(8):1656-1669. PubMed ID: 32324888
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
15. Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2024 Mar; 4(3):785. PubMed ID: 38477691
[No Abstract] [Full Text] [Related]
16. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Powderly JD; Klempner SJ; Naing A; Bendell J; Garrido-Laguna I; Catenacci DVT; Taylor MH; Lee JJ; Zheng F; Zhou F; Gong X; Gowda H; Beatty GL
Oncologist; 2022 Nov; 27(11):905-e848. PubMed ID: 36156099
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Park H; Shapiro GI; Gao X; Mahipal A; Starr J; Furqan M; Singh P; Ahrorov A; Gandhi L; Ghosh A; Hickman D; Gallacher PD; Wennborg A; Attar EC; Awad MM; Das S; Dumbrava EE
ESMO Open; 2022 Oct; 7(5):100573. PubMed ID: 36084396
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Salous T; Shukla NA; Althouse SK; Perkins SM; Furqan M; Leal T; Traynor AM; Feldman LE; Hanna NH; Durm GA
Cancer; 2023 Jan; 129(2):264-271. PubMed ID: 36420773
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
[TBL] [Abstract][Full Text] [Related]
20. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
